Rheonix to Host Workshop and Showcase Easy-to-Use, Cost-Effective Molecular Diagnostic Technology at AMP 2015

ITHACA, N.Y. – Rheonix Inc., a developer of fully automated molecular testing solutions, will host a workshop at the Association for Molecular Pathology (AMP) 2015 Annual Meeting, which will be held Nov. 4-7 at the Austin Convention Center in Austin, Texas. The workshop, “Meeting the Challenges of the Changing LDT Landscape: Tools for Compliance,” will take place at 12 p.m., Nov. 4 in room 18B at the Convention Center. Throughout the annual meeting, Rheonix will showcase its Encompass Optimum™ platform at booth 1315.

During the workshop, Richard A. Montagna, Ph.D., FACB, senior vice president for scientific and clinical affairs at Rheonix, will discuss pending regulatory changes recommended by the Food and Drug Administration for laboratory developed tests, identify challenges, and present tools designed to work within the current and proposed guidelines from the agency. Montagna will also address how a fully automated, multiplexed open platform can be used to design and validate molecular assays that are developed in-house and will present data from assays using a disposable Rheonix CARD® cartridge and universal capture probes.

Rheonix was recently granted patent 9,132,398, “Integrated Microfluidic Device and Methods,” for its CARD cartridge, which enables assays to be performed on the company’s Encompass platform. The dual-layer design of the Rheonix CARD delivers a fully automated molecular assay at a fraction of the cost of other options by manipulating reagents internally with its active fluidic network of pumps, valves and channels, thus eliminating the potential for contamination, reducing user error and streamlining workflow.

“In addition to regulatory changes, labs today are facing obstacles such as inefficient workflow, limited budgets and a lack of trained staff, which create an environment that is receptive to workforce multipliers and automated systems like the Encompass Optimum and CARD cartridge,” said Steve Pemberton, vice president of marketing and sales, Rheonix. “We’ve developed a first-of-a-kind system that emphasizes both throughput and multiplex and incorporates totally open software that allows users to build their own sample-to-answer complex molecular tests, even with a limited staff. We’re helping bring powerful molecular tools to laboratories that could not previously afford to purchase or run them.”

The Encompass Optimum is an automated system that streamlines workflow for building and implementing molecular assays as a nonclinical tool. It is a platform with unmatched versatility that allows users the flexibility to configure their own testing and control all aspects of assay performance, while keeping the testing simple and maintaining the instrument’s ease of use. The Encompass Optimum can dramatically decrease the complexities of creating user-defined testing, while increasing efficiency and accuracy. The product’s automation, capability for high throughput and high-complexity assays, and unique sample-to-result system allows the platform to solve workflow inefficiencies within many research labs.

For more information on Rheonix, visit www.rheonix.com.